Phase 2 Heart Disease Trial, Recruiting NCT05472337 Sponsor: Pontificia Universidad Catolica de Chile Condition: Heart Disease
Back to Heart Disease

Phase 2 Heart Disease Trial, Recruiting

NCT05472337
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older
  • People who are currently admitted to the Clinical Hospital of the Catholic University with a heart condition involving chest pain and elevated blood markers of heart damage (with or without changes on a heart tracing test)
  • People who are scheduled to have a procedure to look at the arteries of the heart (coronary angiography), with a planned procedure to open any blockages, during the same hospital stay
  • People who are willing and able to sign a written consent form agreeing to take part

Who may not be able to join:

  • People having a major type of heart attack (called an ST-elevation myocardial infarction) that requires emergency treatment immediately, as there would not be enough time for the study medication to work
  • People with a severe narrowing of the main artery supplying the heart (left main stenosis)
  • People with advanced heart failure where the heart is pumping at less than 35% of its normal capacity
  • People who have had a previous reaction or intolerance to the study drug colchicine, or who are already taking it for another condition such as gout
  • People with severe liver disease or abnormal liver test results above a certain level
  • People with certain blood count abnormalities (low white blood cell or platelet counts)
  • People with significantly reduced kidney function
  • People taking certain medications that interact with colchicine (including CYP3A4 inhibitors or calcineurin inhibitors)
  • People with an active autoimmune disease or who regularly take anti-inflammatory medications
  • People with an active infection at the time of the trial
  • People who are pregnant or breastfeeding
  • People with any other illness that limits life expectancy to less than one year
  • People with a medical history of a condition that the treating doctor believes would put them at significant risk if they joined the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Gonzalo Martínez, MD, Pontificia Universidad Catolica de Chile

Phone: 56 223543218

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Pontificia Universidad Catolica de Chile
Registry
ClinicalTrials.gov
Start date
1 August 2022
Est. completion
30 March 2026

Where this trial is recruiting

🇨🇱 Chile

Primary endpoints

Change in Index of Microcirculatory resistance (IMR) between pre and post-coronary angioplasty.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov